Risk of thromboembolic events in elderly patients receiving intravitreal ranibizumab or bevacizumab for age-related macular degeneration or macular oedema

Trial Profile

Risk of thromboembolic events in elderly patients receiving intravitreal ranibizumab or bevacizumab for age-related macular degeneration or macular oedema

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top